J&J to use drug delivery device for HBV vaccine thanks to $85M partnership

J&J's ($JNJ) Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B. Ichor will receive up to $85 million via an upfront payment, R&D support and development sales milestone payments, as well as royalty payments on future licensed product sales. The device sends short electrical pulses that temporarily open cell membranes. Ichor signed a similar agreement with Pfizer ($PFE) in February for use with the pharma bigwig's preclinical cancer vaccine-based immunotherapies. More from FierceMedicalDevices

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…